Actavis selling brands to win FTC nod for Warner buy; Roche's Kadcyla beat rivals at holding off HER2+ breast cancer;

breast cancer

@FiercePharma: Trending on our website (still): If pharma reps can't get in doctors' front doors, try alternate routes. Story | Follow @FiercePharma

@EricPFierce: U.K. tosses lean, but important bone to pharma with expected extension of cancer drug fund. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. Story | Follow @CarlyHFierce

> Actavis ($ACT) agreed to sell off three oral contraceptives and an osteoporosis treatment to win Federal Trade Commission (FTC) approval for its $8.5 billion Warner Chilcott ($WCRX) buyout. Report

> Roche's ($RHHBY) new breast cancer treatment Kadcyla beat its older drug Herceptin and GlaxoSmithKline's ($GSK) Tykerb at holding off cancer growth in patients with HER2-positive disease. Report

> GlaxoSmithKline agreed to sell its thrombosis drugs and a related factory to Aspen Pharmacare for £700 million, or about $1.3 billion. Report

> Belgium's UCB won FDA approval for its anti-inflammatory drug Cimzia as a treatment for adults with psoriatic arthritis. Report

> An official Japanese panel found that Novartis ($NVS) may have violated domestic law on drug promotions with ads for its blood-pressure drug Diovan that cited flawed research. Report

> The FDA warned that Pfizer's ($PFE) high-powered antibacterial drug Tygacil increases the risk of death and said the company would add a "black box" warning to the drug's label. Report

> Hungarian watchdogs approved France-based Servier's offer to buy the shares of the drugmaker Egis that it doesn't already own. Report

Medical Device News

@FierceMedDev: Device tax at center of government funding battle. Article | Follow @FierceMedDev

@MarkHFierce: KKR made it official, grabbing an 80% stake of Panasonic's healthcare arm for $1.67B - much higher than predicted. ICYMI Friday | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Medtronic lands U.S. approval of early-generation artificial pancreas. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Intersect plugs positive drug-eluting sinus implant data. Item

> Life Tech to peddle Advanced Cell Diagnostics' RNA biomarker tech around the world. More

> KCI absorbs two acquisitions into wound care mega-company. Article

Biotech News

@FierceBiotech: AstraZeneca CEO celebrates 1st anniversary with promising lung cancer data. More | Follow @FierceBiotech

@JohnCFierce: Pfizer nabs autoimmune disease drug rights for $25M upfront. News | Follow @JohnCFierce

@DamianFierce: Few are optimistic about a last-minute budget deal. Here's what happens at the FDA after a shutdown: Article | Follow @DamianFierce

> Lundbeck to cull 200 staffers in cost-cutting drive. Item

> Relypsa pitches $126M IPO as lead CKD drug nears moment of PhIII truth. Story

> Achillion shares crushed in a rout as hep C blockbuster hopes fade. Article

> Roche's new round of lung cancer data keeps spotlight on immunotherapies. More

CRO News

> Quintiles jumps into personalized medicine for cancer trials. More

> Merged at last, PRA and RPS say they're fourth-largest CRO. Report

> InVentiv launches doc network for late-stage trials. Story

> JSS snaps up Latin American CRO. Article

> Parexel launches China-focused service as local demand heats up. News

Biotech IT News

> FDA taking hands-off approach to regulation of most apps. More

> Genohub talks up 'Kayak' for NGS services. Report

> NIH calls for comments on draft genomics data sharing policy. Story

> Business behind Google Earth for the human body raises $4M. Item

> Pfizer to give patients access to their trial data. Article

And Finally... Increased government healthcare spending led to better numbers on cancer survival in the EU, a study found. Report